UK property hotspots: Top 5 UK cities for house price growth

While the average UK house price continues to grow steadily amid economic headwinds, some areas are seeing prices surge well beyond the UK average.

Recent data reveals the cities leading the charge across the UK, with several proving real powerhouses for average house price growth.

Top 5 UK cities for annual house price growth

According to Zoopla’s House Price Index for September 2025, these cities are experiencing the strongest annual price growth:

  1. Belfast – 7.9%
  2. Liverpool – 3.0%
  3. Manchester – 2.6%
  4. Newcastle – 2.3%
  5. Glasgow – 2.1%

Belfast is the clear leader, with house price growth more than double that of any other major UK city. The average property price in Belfast now stands at £195,400, making it both a growth hotspot and one of the more affordable major cities for buyers.

The North-South divide deepens

A pattern emerges from the data: all five top-performing cities are located in the north of the UK or in Northern Ireland. This reflects a widening geographical divide in the housing market that favours the north of England and Northern Ireland.

Zoopla’s analysis shows that house price inflation is running at over 2% across Scotland, Wales, and northern regions of England. In stark contrast, house price inflation has “come to a standstill” across southern regions of England, where affordability pressures and weaker demand are limiting price increases.

London, traditionally a powerhouse of property price growth, recorded just 0.1% annual growth in September 2025, with an average price of £529,800. Other cities in the south of England are faring even worse, with Bournemouth recording negative growth of -1.9%.

National picture: steady but modest growth

Both Zoopla and Nationwide report similar national trends, though with slight variations in their figures:

  • Zoopla reports UK house price inflation at 1.3% (September 2025)
  • Nationwide reports annual growth at 2.4% (October 2025), with an average UK house price of £272,226

Zoopla’s data indicates that the average UK house price stands at £270,000, whilst their analysis reveals that sales agreed are down 3% year-on-year, marking the first annual decline in sales agreed in two years.

What’s driving regional variations?

Affordability remains the key factor differentiating regional markets. Northern cities and Belfast offer significantly better value, with average prices well below the national average, making them attractive to first-time buyers and investors. Rental yields can be more attractive in these regions.

Southern England’s affordability challenges, combined with higher stamp duty costs and speculation about potential property tax reforms, are dampening demand and constraining price growth.

For buyers seeking growth potential and relative affordability, the message is clear: look north.

Three dividend shares for consideration

We take a look at three dividend shares with strong income characteristics and yields that beat the benchmark FTSE 100 dividend yield of around 3.2%.

Our dividend shares for consideration include a UK equity trust, an exciting small-cap, and a FTSE 100 stalwart.

Dunedin Income Growth Investment Trust

The Dunedin Income Growth Investment Trust (DIGIT) offers an attractive proposition for income-focused investors seeking sustainable, growing dividends from UK equities.

DIGIT offers an attractive 6.5% dividend yield, substantially ahead of both cash rates and the FTSE All-Share Index. The trust is also targeting a 34% dividend increase next year.

The Trust boasts a 43-year track record of maintaining or growing its dividend, demonstrating resilient income delivery through multiple market cycles and periods of volatility. This could be particularly valuable given that global equities are trading near highs.

The Trust’s differentiated positioning includes 49% invested in sub-£10 billion companies and 17% in European holdings, providing investors with exposure beyond the mega-cap dominated FTSE All-Share.

Investors choosing the trust will benefit from a “triple discount”. Quality stocks are undervalued relative to the market, the UK market trades at a substantial discount to global equities, and the trust’s shares trade at a discount to net asset value.

Adsure Services

Aquis-listed Adsure Services has consistently increased its dividend since listing in 2023, and it yields 7.6% at the current share price of 25p.

The dividend is backed by recurring revenues from long-term contracts with government-funded organisations. Supporting its ability to increase dividends in the years to come is its ‘Fit for the Future’ strategic initiative that aims to drive underlying efficiencies through the deployment of cutting-edge technologies.

In addition to the deployment of new software to enhance the work of its internal audit operatives, the company is readying the launch of its proprietary ‘TIAA Insight’ AI tool designed to improve key utilisation metrics.

This promises to drive further expansion of Adsure’s EBITDA margin, which rose to 11.8% from 9.4% in the year ended 31 March 2025. EBITDA jumped 35% during this period.

This is a company to tuck away and await further growth. 

BP

BP is an age-old income favourite. Yes, it’s involved in oil extraction that isn’t ESG-friendly, but BP’s scale and ongoing demand for fossil fuels will support earnings in the years to come.

It’s also an ‘ugly duckling’ of a stock that has detached from its intrinsic value and lags behind peers such as Shell in terms of valuation.

Recent results were unspectacular but reaffirmed its ability to generate cash as operating cash flow rose to $7.8bn in the third quarter. Lower oil prices presented a headwind during the period, and investors will be pleased to see OPEC+ taking measures to manage the supply glut, which has weighed on prices.

BP is streamlining its business through a series of divestments that will bolster the balance sheet and provide a strong base for future growth.

With a 5.2% dividend yield, BP offers both value and the potential for capital appreciation. The firm is also committed to share buybacks, announcing $750m in fresh purchases this week.

A worthy addition to any income portfolio.

Vistry on track to meet full year expectations

Vistry said it is confident it can deliver profit growth in FY25 in a trading statement released on Thursday, pointing to strong demand from its partner model despite challenging market conditions.

The group said demand from Registered Providers and Local Authorities has continued to strengthen significantly, and the company expects to conclude several new Partner Funded deals in Q4.

It was surprising to see shares dip in early trade, but the weakness was bought into, and Vistry turned positive as the session progressed.

Vistry’s overall sales rate since July 1st has jumped 11% compared to the same period last year, reaching 0.81, up from 2024’s 0.73.

Perhaps investors were put off by the falling order book, which fell to £4.3 billion from £4.8 billion in 2024.

“Vistry’s showing signs of returning to life after a dismal period of operational slip-ups and profit guidance downgrades, as the group saw its sales rates climb 11% higher so far in the second half,” explained Aarin Chiekrie, equity analyst, Hargreaves Lansdown.

“Importantly, the UK government’s £39 billion pledge to increase the amount of affordable housing is having the desired effect. The money is starting to flow, and that’s seen partner-funded activity pick back up, with several new deals expected to be confirmed in the final quarter. As these houses are built, that will convert into revenue and should help the top line return to growth territory.”

“House prices are on the rise, demand is outstripping supply, and build-cost inflation remains at manageable low single-digit levels, with the latter being helped by Vistry’s huge scale, allowing it to negotiate harder on building materials.”

Vistry said build cost inflation remains controlled at low single digits, with material pricing having stabilised, while labor cost pressures are being managed through improved work visibility and continuity.

Filtronic secures €7m multi-year contract with leading European aerospace manufacturer

Filtronic plc has landed a €7 million contract to supply RF assemblies for a major Low Earth Orbit (LEO) satellite constellation programme.

The three-year deal with a leading European aerospace manufacturer marks another milestone for the UK-based RF solutions specialist after announcing a string of new wins this year, including several with Elon Musk’s SpaceX.

Filtronic will produce complex RF assemblies in-house, specifically designed for the harsh conditions of the space environment.

The LEO satellite constellation market is experiencing rapid growth as companies race to provide global broadband coverage. Multiple operators are launching thousands of satellites to create these constellations, creating substantial opportunities for specialised suppliers like Filtronic.

“This contract highlights our increasing diversification across customers within the space markets and reflects the trust placed in Filtronic’s capability to deliver at scale for the most demanding space applications,” said Nat Edington, Chief Executive Officer.

“As demand for satellite connectivity continues to grow, this is another milestone in Filtronic’s mission to support the growing satellite market for Non-Terrestrial Networks, Mobile Satellite Services, and Direct-to-Device connectivity.”

AIM movers: OPG Power Ventures buyback and Velocity Composite held back by Airbus 350 production

9

Power generator OPG Power Ventures (LON: OPG) is launching a tender offer of up to 182 million shares at 6.27p/share. This is part of the plan to leave AIM. The proposal will be put to shareholders at a general meeting on 3 December. The share price has rebounded 10.1% to 6p.

Cybersecurity services provider Corero Network Security (LON: CNS) had a better third quarter and the order intake was $7.4m. There was an expanded renewal with the largest customer. The total contract value is $6.8m and only $800,000 is included in the third quarter intake. Full year revenues are still expected to be $24m-$25.5m. The share price increased 7.43% to 9.4p.

Leak detection services provider Water Intelligence (LON: WATR) has increased nine months revenues by 9% to $69.3m and EBITDA is $13.9m. his covers more than 80% of the full year forecast. A further $900,000 has been spent on buying back shares and this will enhance earnings. The share price rose 4.92% to 277p.

Workplace optimisation software provider Checkit (LON: CKT) chief executive Kit Kyte has bought a further 117,646 shares at 17p each. The share price improved 5.88% to 18p.

Grocery distributor Kitwave (LON: KITW) says 12 month figures to October 2025 are in line with the previously downgraded forecasts. The year end is being changed to December. Two depots have been closed and there could be further rationalisation. Gross margins should start to recover following a period of reduced margins to retain customers. The share price recovered 4.61% to 215.5p.

FALLERS

Aerospace composite components manufacturer Velocity Composites (LON: VEL) has been hit by lower than expected Airbus A350 production. This is due to supply chain issues at Airbus. There have also been delays in programme transfers in the US. Dowgate has cut its full year revenues forecast from £23m to £20.7m. This means that the loss would be £900,000. The share price decreased 20.5% to 17.5p.

Union Jack Oil (LON: UJO) has a 53% interest in the Sark well in Oklahoma and a production test failed to identify commercial hydrocarbons. The share price slipped 11.8% to 3.35p.

Mongolia-focused Petro Matad (LON: MATD) says the Gazelle-1 well is producing and the daily production has more than doubled to 350 barrels of oil. Heron-2 could further increase production. The company is in talks with PetroChina to end the withholding of 30% of invoiced sales. Shore maintains the fair value of 6.1p/share. The share price fell 15.9% to 1.325p.

FTSE 100 stablises after US tech selloff

The FTSE 100’s defensive attributes were on display on Wednesday after tech shares sent US indices sharply lower overnight.

The S&P 500 closed 1.1% lower, while the tech-heavy NASDAQ sank 2.2%.

US tech names, including Nvidia, Tesla, Micron Technology, Uber, Dell, and Palantir, were all heavily hit by concerns about lofty valuations throughout the sector.

“The AI-investment boom that has fuelled the rally in 2025 has created exceptionally high expectations for continued earnings growth, but recent signs of cooling demand, rising costs, and tighter policy conditions have prompted investors to question whether those valuations are still justified,” said Daniela Hathorn, Senior Market Analyst at Capital.com.

Europe lacks significant exposure to tech shares, especially those that have been bid up to eyewatering valuations, so there was minimal fallout in London on Wednesday.

“Market jitters around US tech stocks might have put investors on the edge of their seats, but yesterday’s sell-off wasn’t severe enough to cause widespread panic,” said Russ Mould, investment director at AJ Bell.

“A 2% decline in the Nasdaq index and a 10.7% jump in the Vix fear gauge were like a sharp bout of turbulence on a flight – unpleasant, but just for a moment. The fact a major sell-off didn’t occur across the whole of Asian and European markets following Wall Street’s wobble implies that we’re not at the start of the correction many people have feared. Futures prices point to a less dramatic day in the US when trading opens later today.”

The FTSE 100 was trading down around 0.1% at the time of writing, but is less than 1% away from all-time highs.

Coca-Cola Europacific Partners was the FTSE 100’s top riser, up 1.9%, after the drinks firm reaffirmed guidance after steady growth in its European business.

Damian Gammell, Chief Executive Officer of Coca-Cola Europacific Partners, said: “2025 continues to be a solid year for CCEP, reflecting our great brands, great people, great execution and strong relationships with our brand partners and customers. We’ve delivered another quarter of volume growth in Europe, despite softer consumer demand. We continue to drive underlying growth in APS, excluding portfolio changes in Australia, and despite macro driven challenges in Indonesia.

Barratt’s was also among the gainers after releasing a trading statement that pointed to resilience amid concerns about the upcoming budget. Shares were 1.7% higher at the time of writing.

Weir Group was the FTSE 100’s top faller, dropping 2.3%, as investors took the release of a Q3 trading update as a cue to book profits. There was nothing overtly negative about their update with guidance maintained.


.

Marks & Spencer confirms cyber attack hit to profits

Marks & Spencer has confirmed the cyber attack led to £100m in costs, ravaging the group’s operating profit for the 26-week period ended 27th September.

Operating profit for the period fell to £184.1m from £413.1m in the same period last year despite sales rising 22% to £7.9bn.

The jump in revenue, however, was entirely due to the introduction of Ocado Retail revenue, accounting for around £1.5bn.

Stripping out Ocado Retail, M&S sales were flat. Ocado Retail, incidentally, is still loss-making.

Shares were little changed on Wednesday, with much of the bad news priced in. M&S had previously warned that the cyber attack could cost £300m.

“It had all been going so well at Marks & Spencer,” said Mark Crouch, market analyst for eToro.

“But as chief executive Stuart Machin put it, the first half of this year was “an extraordinary moment in time for M&S”, and that’s putting it mildly. The retailer’s underlying profit slumped 55%, laid low by the fallout from April’s cyberattack that crippled its website and halted online clothing orders for seven weeks. Click-and-collect services were down for nearly four, and food operations weren’t spared either.

“The damage shows most starkly in fashion and home, where profits collapsed by more than 80% to £46.1 million, and sales tumbled 16.4% to just under £1.7 billion.”

“It’s a bitter blow for a brand that had been flying high, finally shaking off its dowdy image and delivering the kind of retail renaissance investors had only dreamed of. That the share price has held up so resiliently is testament to the strength of the turnaround before the hack, but 2025 now looks like a year of what-ifs.”

Wetherspoons sales growth outperforms pub industry average

The struggles of the hospitality industry are well-documented. Wetherspoons, however, is outperforming the wider industry and making the best of a bad situation.

In the first 14 weeks of the financial year, like-for-like sales rose 3.7% year-on-year. Bar sales climbed 5.7%, whilst food grew a modest 0.9% and slot machines jumped 8.9%. Hotel room sales fell 6.3%.

Total sales increased 4.2% year-to-date.

“J D Wetherspoon’s sales growth has slowed in the first fourteen weeks of the financial year to 3.7%. At the last check, that number stood at 3.2% for the first nine weeks, so investors should take some comfort in the pub chains continued resilience,” said Derren Nathan, head of equity research, Hargreaves Lansdown.

The CGA RSM Hospitality Business Tracker, which monitors monthly like-for-like sales across multi-site pub and restaurant operators, reported industry sales of 0.2% in September. Investors will take some solace in the fact that Wetherspoon posted 3.4% growth for the same period.

The pub chain has now outperformed the industry tracker for 37 consecutive months.

But, arguably, the most interesting part of today’s trading update was the criticism of the UK government by the Wetherspoons Chairman:

“In our recent annual report, it was stated that a “main lesson of the 1970s (is that) if energy prices go up… inflation results and almost everyone is poorer,” said Wetherspoon chairman Tim Martin.

“The point was also made that the proposed development of “standby” nuclear power, for periods when wind and solar energy were unavailable, would require the UK to approximately match France’s 59 nuclear reactors.

“However, the UK has only nine nuclear reactors today, most of which are due to be decommissioned by 2030.

“So far, the logic of the points made in the annual report has not been questioned and more detailed arguments, emphasising the need for wider public debate, are advanced in the most recent edition of Wetherspoon News.

“A second point made in the annual report is the startling fact that none of the chairmen of the mega-successful US technology companies (Microsoft, Apple, Meta, Amazon, Nvidia etc) comply with UK corporate governance guidelines, which include, for example, a ludicrous “nine-year rule”.

“As a matter of common sense, few sensible technology entrepreneurs would envisage a London flotation for this reason alone.

“Perhaps the UK powers-that-be don’t feel we need to try and attract these sorts of companies. However Nvidia, alone, is apparently worth nearly one and a half times the capitalisation of the entire London stock market.

“I have written about the absurdities of corporate governance for many years- for example in this article from 2014. Strangely, almost no one has ever contradicted the points made- yet nothing much has changed either.

“A final and related point concerns wages and taxation. The average price of a pint in pub is about £5.16 and labour is about 35% of the ex-VAT sales price (Mitchells & Butlers 36.2%, FY24), about £1.50 per pint.

“A supermarket pint costs about £1.50 and labour is about 12% of the ex-VAT sales price (Tesco 12.0%, FY24), about £0.15 per pint.

“Therefore, it can be seen that a 10 per cent wage rise will increase the cost of a pint by about 15 pence in a pub versus about 1.5 pence in a supermarket.

“Increased labour costs are, consequently, dramatically widening the pricing differential between pubs and supermarkets, to the anger and consternation of customers. 

“A further widening of the differential results from pubs paying 20% VAT on food sales, whereas supermarkets pay nothing.

“As investment bank Morgan Stanley pointed out in recent research, pubs have lost 50% of their beer volumes to supermarkets since the year 2000- price is surely the main culprit.

“It is important to emphasise the above points since it’s not clear that they are fully appreciated by legislators, economists or the public.

“The company is pleased with the continued sales momentum but is mindful of the Chancellor’s Budget statement later this month and, as a result, is slightly more cautious in its outlook for the remainder of the year.”

Barratt Redrow shakes off budget-induced uncertainty

Barratt Redrow has shaken off concerns about the budget over the past 17 weeks, enjoying increased completions and an increased orderbook.

Although the group pointed to tough market conditions caused by the UK government’s fiscal policies, Barratt completed 3,665 homes in the period to 26 October, up 7.9% year on year.

There were some signs of weakness, however, with weekly private reservations slipping to 0.57 from 0.59. The group is now operating an average of 402 sales outlets, down from 433 previously.

The forward order book stood at 10,669 homes valued at £3.28bn, marginally ahead of last year’s £3.21bn.

Chief Executive David Thomas said the firm remained “uniquely well positioned” with three strong brands and a high-quality land bank. The group is targeting 22,000 completions annually over the medium term.

The integration of Redrow continues to deliver cost benefits. The firm confirmed cost synergies have reached £80m of a £100m target, up from £69m in June.

“Barratt Redrow continues to build on strong foundations, despite pre-Budget uncertainty weighing on the Autumn market for housebuilders,” said Aarin Chiekrie, equity analyst, Hargreaves Lansdown.

“Nerves about potential incoming changes to taxes, both in the property market and wider economy, have led to a slight slowdown in sales rates over the 17 weeks to 26 October. Helping to ease the pressure, robust house prices and a favourable sales mix have seen the order book swell slightly higher to £3.3 billion. The integration of Redrow is continuing at pace, expected to deliver another £45 million of cost-savings this financial year,”

Barratt Redrow maintained its full-year guidance of 17,200 to 17,800 completions, with around 40% expected in the first half. The company is 60% forward sold for the year.

“Achieving this target relies on normal trading patterns over its financial year, as well as the potential impact from the Chancellor’s Budget later this month,” Chiekrie said.

“With speculation swirling that manifesto-breaking tax rises are on the cards, it could weigh on affordability for house buyers and profits for housebuilders, proving particularly unpopular among the masses.”

Healthcare sector at an inflection point: The investment case for Polar Capital Global Healthcare Trust

Investors find the healthcare sector at a potential inflection point. After years of delivering steady and attractive growth driven by several long-term trends, cutting-edge innovation, and favourable market conditions, the industry has recently struggled with poor investor sentiment, weighed down by political uncertainty.

Yet according to the specialist team behind Polar Capital Global Healthcare Trust (PCGH), the fortune of the sector may be about to turn. Their trust presents an attractive opportunity for long-term investors willing to look beyond near-term noise.

Despite recent softness in the healthcare sector, deft stock selection and a structure that allows the managers to invest across the full spectrum of healthcare companies means PCGH’s net asset value has grown over 80% since 2017, when the Trust was reconstructed as Polar Capital Global Healthcare Trust plc. The sector is now trading at very compelling valuations, well below recent highs.

PCGH benefits from one of the most experienced healthcare investment teams in the industry.  The broader team comprises eight dedicated healthcare specialists with nearly 150 years of combined industry experience, managing £3.5 billion in team assets as of 30th September 2025, invested across all healthcare subsectors and market caps.

Why Healthcare?

First, we must address the question of why investors should consider the Healthcare sector. The Healthcare sector presents a unique opportunity for investors. It’s one of the few sectors that combines defensive characteristics with substantial growth potential, driven by strong demand dynamics and near constant innovation.

Underpinning the favourable characteristics of the sector, global demographics provide a significant tailwind for the industry. The US senior population is expected to climb from approximately 55 million in 2020 to around 83 million by 2050. There is a similar trajectory in Europe which will likely also be observed in many emerging markets in years to come. Aging populations naturally translate to higher demand for treatments, diagnostics, hospital services, and long-term care. 

The sector is supported by innovation that is accelerating with the introduction of AI. Breakthroughs in gene editing, immuno-oncology, precision medicine, and AI-driven diagnostics are transforming how diseases are treated and prevented.

Clinical studies are exploring how newly developed drugs can manage cardiovascular risk, kidney disease, and even Alzheimer’s, while weight-loss drugs continue to capture industry and investor interest.

The explosion of weight loss drugs from companies like Novo Nordisk and Eli Lilly has reshaped the pharmaceutical landscape, creating a multi-billion-dollar global market almost overnight. Both companies were held by the Trust as the market developed. Eli Lilly was the top holding as of 30th September 2025.

Beyond weight loss therapies, there is a strong pipeline of new drugs and innovations that will provide future opportunities for the trust and its investors.

The long-term performance of the sector reflects the innovation it produces. Global Healthcare is projected to deliver earnings growth of 7.3% annually between 2007-2026 – comfortably ahead of the MSCI All Country World Index’s 6.5%. This lower earnings volatility is underpinned by those long-term growth drivers, making healthcare an attractive proposition during periods of market uncertainty.

Healthcare is out of favour

Despite these compelling fundamentals, healthcare has been out of favour.

The sector has underperformed significantly. In Q2 2025, the S&P 500 Healthcare Index experienced one of its worst quarters relative to the broader market in recent history –  a performance only comparable to when the Clinton administration threatened sweeping policy changes back in 1993.

This time around, it was again the threat of changes in US policy that drove the sector downwards, but on multiple fronts. Investors grappled with the Trump administration’s announcement of pharmaceutical industry-specific tariffs and the threat of a ‘most favoured nation’ (MFN) drug pricing plan for US government-funded healthcare.

There was also continuing fallout from the controversial appointment of Robert F Kennedy Jr as Secretary of Health and Human Services.

However, the team at Polar Capital believe we have likely hit peak fear, and the sector could be about to turn, highlighting the valuation discount between the sector and the wider market.

Relative valuation

Healthcare’s relative valuation compared to the S&P 500 is in line with lows seen only three times in the past 36 years.

Importantly, the S&P 500 Healthcare Sector’s relative forward P/E ratio has shrunk to levels that historically preceded strong recovery phases. Although this by itself is not a predictor of an imminent rally, such dislocations rarely last for long, especially for a sector the size of the healthcare sector.

Looking at a past dislocation as an example and the 2015 biotech correction, when valuations contracted sharply, the Nasdaq Biotech Index rebounded by more than 60% over the following five years.

Indeed, after two of the previous three major healthcare de-ratings over the past 36 years, a bull market ensued.

Supporting the case for a recovery in the sector, Polar Capital highlights thatHealthcare sector ETF’s have experienced outflows on a rolling 1-year basis for a prolonged period going back to 2023.  They see this as a ‘powerful contrary indicator’.  

In addition to market pricing, the macro environment is showing signs of improvement.

In September, greater detail emerged on Donald Trump’s tariff plans for the sector and MFN pricing issues.

President Trump did as he promised announced a 100% tariff on branded pharmaceutical imports, but crucially, the tariff will not apply to companies building or expanding manufacturing facilities in the US.  Most large pharmaceutical companies have already announced significant investments in US capacity. The UK’s AstraZeneca, for example, plans to invest $50bn in US manufacturing.

More significantly, on the final day of September, the US government and Pfizer reached an agreement adopting MFN pricing for certain channels in exchange for a three-year moratorium on tariffs.

This agreement reflects a willingness on both sides to negotiate in a way that preserves the sector’s ability to invest in innovation.

While uncertainty remains about whether further concessions will be required, we mustn’t underestimate the clarity recent developments give the sector.

Fundamental growth drivers remain firmly intact

Despite all the negativity, the sector is in a strong position with higher utilisation and new product launches being key drivers for growth.

With a few exceptions, the Q2 2025 results season underlined this strength and provided reassurance.

As Gareth Powell, Head of Healthcare at Polar Capital, notes: “Valuations have now been pulled down to such an extent that the potential returns from here for healthcare stocks look extremely compelling. As evidence of this, despite the concerns over US government policy, M&A activity is starting to pick up again.”

Investment approach and strategy

PCGH’s investment objective is straightforward: to generate capital growth by investing in a diversified global portfolio of healthcare stocks.

The Trust invests primarily in listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices, and biotechnology, diversified by geography, industry sub-sector, and investment size.

Healthcare is an extraordinarily diverse and rapidly evolving sector. It is far more complex than simply buying and holding a few large-cap pharmaceutical stocks and this is reflected in PCGH’s approach.

The portfolio structure is designed to balance defensive growth with emerging innovation.This approach allows PCGH to combine the stability and cash generation of established healthcare leaders with exposure to the high-growth potential of smaller innovative companies.

This is a combination difficult to achieve through passive or single-strategy approaches. PCGH’s active closed-ended approach is something that sets them apart from other vehicles and adds an enviable dimension to its proposition.

Six Investment Themes

The team focuses on six key investment themes that they believe will drive returns over the next 5-10 years:

  1. Healthcare Delivery Disruption – Telehealth, robotics, ambulatory surgery centres, and home health are shifting utilisation to lower-cost settings
  2. Innovation – Gene and cell therapy, targeted oncology, novel vaccines, and rare disease treatments addressing high unmet medical needs
  3. Consolidation – M&A activity that is accretive to growth and returns, bringing complementary technologies and pipeline assets
  4. Emerging Markets – Accelerating investment and regulatory flexibility creating strong growth prospects among 5 billion people with increasing wealth
  5. Outsourcing – Contract Research Organisations, manufacturing, and real-world data driving productivity improvements
  6. Prevention – Diagnostics, vaccines, remote monitoring, and co-ordinated care representing the best healthcare strategy

Artificial intelligence and machine learning are being adopted across all these themes to drive efficiencies and superior outcomes.

Polar Capital Global Healthcare Trust

In addition to the strength of the portfolio and attractiveness of current healthcare valuations, Polar Capital Global Healthcare Trust has another allure in the upcoming tender offer and changes to its charging structure.

The Trust will remove its fixed-life structure and replace it with a rolling five-year tender offer mechanism, starting with an initial 100% tender offer to all shareholders in November, and repeating every five years thereafter.

Other proposals that will benefit investors include removing the performance fee, adopting a tiered management fee structure, and implementing active discount management through share buybacks.

The investment strategy remains unchanged. However, there is a notable tweak to the Trust’s allocation policy that allows up to 30% to be invested in small and mid-cap companies.

Polar Capital Global Healthcare Trust presents an opportunity for investors who want to secure the stable and growing cashflows of the world’s largest healthcare firms, but also want to employ the specialist support of managers who have the ability to identify those smaller companies that may well become the world’s next pharma or healthcare giant.

And we believe the timing for the sector couldn’t be much more attractive.